AXIM Biotechnologies, Inc.

OTCPK:AXIM Stock Report

Market Cap: US$1.3m

AXIM Biotechnologies Management

Management criteria checks 4/4

AXIM Biotechnologies' CEO is John Huemoeller, appointed in Jan 2019, has a tenure of 5.75 years. total yearly compensation is $420.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 1.98% of the company’s shares, worth $24.84K. The average tenure of the management team and the board of directors is 3.1 years and 3 years respectively.

Key information

John Huemoeller

Chief executive officer

US$420.0k

Total compensation

CEO salary percentage100.0%
CEO tenure5.8yrs
CEO ownership2.0%
Management average tenure3.1yrs
Board average tenure3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has John Huemoeller's remuneration changed compared to AXIM Biotechnologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-US$4m

Mar 31 2024n/an/a

-US$6m

Dec 31 2023US$420kUS$420k

-US$8m

Sep 30 2023n/an/a

-US$7m

Jun 30 2023n/an/a

-US$9m

Mar 31 2023n/an/a

-US$7m

Dec 31 2022US$5mUS$420k

-US$6m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$15m

Mar 31 2022n/an/a

-US$17m

Dec 31 2021US$420kUS$420k

-US$16m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$9m

Mar 31 2021n/an/a

-US$6m

Dec 31 2020US$2mUS$420k

-US$6m

Sep 30 2020n/an/a

-US$5m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$1m

Dec 31 2019US$2mUS$210k

-US$3m

Sep 30 2019n/an/a

-US$3m

Jun 30 2019n/an/a

-US$4m

Mar 31 2019n/an/a

-US$6m

Dec 31 2018US$45kn/a

-US$7m

Compensation vs Market: John's total compensation ($USD420.00K) is below average for companies of similar size in the US market ($USD667.78K).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.

CEO

John Huemoeller (69 yo)

5.8yrs

Tenure

US$420,000

Compensation

Mr. John W. Huemoeller, II, has been Chief Executive Officer of AXIM Biotechnologies, Inc. since January 2, 2019 and serves as President. Mr. Huemoeller serves as the Chief Executive Officer of Novas. Mr....

Leadership Team

NamePositionTenureCompensationOwnership
John Huemoeller
President5.8yrsUS$420.00k1.98%
$ 24.8k
Robert Malasek
CFO & Secretary8.3yrsUS$90.00k0.017%
$ 207.0
Catalina Valencia
Co-Founder & CEO of Sapphire Biotechno dataUS$187.50k8.29%
$ 104.0k
Kurt Phinney
Chief Operating Officer1.4yrsno datano data
Sergei Svarovsky
Chief Scientific Officer & Co-Founder of Sapphire Biotechno datano data6.54%
$ 82.0k
Douglas Lake
Chief Clinical Officer of Sapphire Biotechno dataUS$164.43kno data
Alim Seit-Nebi
CTO & Co-Founder of Sapphire Biotechno dataUS$82.22kno data
Jeffrey Busby
Senior Vice President of Business Development3.1yrsno datano data
Joseph Tauber
Chief Medical Officer & Chairman of the Medical Advisory Board3.1yrsno datano data
Maria J. Moa
Vice President of Product Development - Sapphire Biotechno datano datano data

3.1yrs

Average Tenure

67yo

Average Age

Experienced Management: AXIM's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John Huemoeller
President7.4yrsUS$420.00k1.98%
$ 24.8k
Joseph Tauber
Chief Medical Officer & Chairman of the Medical Advisory Board3.1yrsno datano data
Timothy Scott
Independent Director7.4yrsUS$20.00k0.11%
$ 1.4k
Kelly Nichols
Member of Medical Advisory Board3yrsno datano data
Robert Cunningham
Independent Director7.4yrsUS$20.00k0.11%
$ 1.4k
Blake Schroeder
Director2.8yrsUS$20.00k0%
$ 0
Michael Stern
Member of Medical Advisory Board2.9yrsno datano data
Henry Perry
Member of Medical Advisory Board3yrsno datano data
Peter O'Rourke
Director4.3yrsUS$20.00k0.083%
$ 1.0k
Laura Periman
Member of Medical Advisory Board3yrsno datano data

3.0yrs

Average Tenure

69yo

Average Age

Experienced Board: AXIM's board of directors are considered experienced (3 years average tenure).